NCT00310674

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age

A Phase III, Single Center, Open Label, Uncontrolled Study to Evaluate the Immunogenicity, Safety and Tolerability, of the Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Premature and Non Premature Children at 3, 5, 11 Months of Age Concomitantly With a Hexavalent Infant Vaccine

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 150 (planned)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 11 Weeks – 15 Weeks
• Healthy volunteers: Accepted

Summary

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 months of age

Conditions

• Prevention of Meningococcal Infection

Interventions

Type	Name	Description
BIOLOGICAL	Meningococcal C Conjugate Vaccine

Timeline

• Start date: 2004-09-01
• First posted: 2006-04-04
• Last updated: 2007-03-13

Locations

1 site across 1 country: Italy